- Home
- DCOM vs NBTX Comparison
DCOM vs NBTX Comparison
Compare DCOM & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCOM
- NBTX
- Stock Information
- Founded
- DCOM 1864
- NBTX 2003
- Country
- DCOM United States
- NBTX France
- Employees
- DCOM N/A
- NBTX N/A
- Industry
- DCOM Major Banks
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- DCOM Finance
- NBTX Health Care
- Exchange
- DCOM Nasdaq
- NBTX Nasdaq
- Market Cap
- DCOM 1.2B
- NBTX 1.3B
- IPO Year
- DCOM 1996
- NBTX 2020
- Fundamental
- Price
- DCOM $27.78
- NBTX $25.71
- Analyst Decision
- DCOM Buy
- NBTX Strong Buy
- Analyst Count
- DCOM 2
- NBTX 1
- Target Price
- DCOM $36.75
- NBTX $8.00
- AVG Volume (30 Days)
- DCOM 177.7K
- NBTX 130.4K
- Earning Date
- DCOM 10-23-2025
- NBTX 09-30-2025
- Dividend Yield
- DCOM 3.59%
- NBTX N/A
- EPS Growth
- DCOM N/A
- NBTX N/A
- EPS
- DCOM 0.87
- NBTX N/A
- Revenue
- DCOM $314,165,000.00
- NBTX $11,930,711.00
- Revenue This Year
- DCOM $49.66
- NBTX N/A
- Revenue Next Year
- DCOM $16.29
- NBTX $114.97
- P/E Ratio
- DCOM $31.81
- NBTX N/A
- Revenue Growth
- DCOM N/A
- NBTX N/A
- 52 Week Low
- DCOM $23.25
- NBTX $2.76
- 52 Week High
- DCOM $37.60
- NBTX $30.35
- Technical
- Relative Strength Index (RSI)
- DCOM 35.20
- NBTX 61.57
- Support Level
- DCOM $27.58
- NBTX $23.31
- Resistance Level
- DCOM $30.56
- NBTX $28.51
- Average True Range (ATR)
- DCOM 0.98
- NBTX 2.22
- MACD
- DCOM -0.28
- NBTX 0.13
- Stochastic Oscillator
- DCOM 7.12
- NBTX 62.43
About DCOM Dime Community Bancshares Inc.
Dime Community Bancshares Inc operates as a holding company. It gathers deposits from customers within its market area and via the internet and invests them in multifamily residential, commercial real estate, commercial and industrial (C&I) loans, and one-to-four family residential real estate loans, as well as mortgage-backed securities, obligations of the U.S. government and government- sponsored enterprises (GSEs), and corporate debt and equity securities. The company has one reportable segment which is Community Banking.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.